In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
The neuronal loss and neurological dysfunction caused by solid stress from brain tumors was reversed by lithium in mice models.
Brain Cancer News
BRAIN CANCER ADVISOR
Brain Cancer News
Liquid Biopsy of Cerebrospinal Fluid Provides Genomic Info on Brain Tumors
Clinical application of cerebrospinal fluid ctDNA analysis remains unclear.
Where Have All the T Cells Gone?
New research proposes a novel mechanism for how tumors sidestep the immune system in patients with intracranial tumors.
Iobenguane I 131 First FDA-Approved Drug For Pheochromocytoma or Paraganglioma
The FDA based its approval on findings from a single-arm phase 2 study, in which researchers treated 68 patients with iobenguane I 131 intravenous injection.
Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma
EGFR-amplified tumors had a high rate of response.
Glioblastoma: Temozolomide, Bevacizumab May Improve Outcomes Among Elderly Patients
Researchers enrolled 66 patients with glioblastoma to evaluate the safety and efficacy of upfront temozolomide with bevacizumab.
Tumor-treating Fields Do Not Negatively Affect Health-related QoL
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
Pediatric Patients Hospitalized for Pneumonia May Have Elevated Cancer Risk
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
Tumor-treating Fields Improve Glioblastoma Outcomes
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
Tumor Treating Fields May Improve Glioblastoma Outcomes
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
Patients With Meningioma Have Inferior Quality of Life Post-surgery
Researchers reviewed data from 1722 patients diagnosed with meningioma between 2006 and 2013 to determine whether the growth itself and/or treatment reduce patient QoL.
FDA Approves Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
Rindopepimut Not Associated With Prolonged Survival in Glioblastoma
At the preplanned interim analysis, the study was discontinued for futility.
Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma
The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.
Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
Better Functional Outcomes With Stereotactic Conformal Radiotherapy for Brain Tumors
Subgroup analyses demonstrated that SCRT particularly benefited patients with a neurological performance scale score of 2 to 3, supratentorial tumors, and patients age 16 or younger.
Want to read more?
Please login or register first to view this content.
